Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Kangmei Pharmaceutical Co., Ltd.    600518   CNE0000017M1

KANGMEI PHARMACEUTICAL CO., LTD.

(600518)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China vows 'zero tolerance' towards illegal market behaviour

07/12/2020 | 08:22pm EST

China will show "zero tolerance" towards securities and accounting fraud and will step up a crackdown on major capital-markets crimes, financial regulators said after a meeting of the Financial Stability Development Committee.

The meeting on Sunday was chaired by Vice Premier Liu He, the cabinet-equivalent State Council said in a statement.

The regulators said they would toughen penalties and establish a crime-busting team with relevant agencies to strengthen cooperation.

They would also deepen the reform of the market's delisting mechanism to weed out bad companies from the country's stock markets.

China has been trying to limit the country's reputational damage after accounting scandals at companies including Kangmei Pharmaceutical and Kangde Xin Composite Material Group.

The China Securities Regulatory Commission (CSR) on Friday punished GF Securities Co for its role in the $12.6 billion financial fraud at drugmaker Kangmei.

GF Securities was banned from the securities-sponsor business for six months, and from bond underwriting for a year.

(Reporting by Brenda Goh and Samuel Shen; Editing by Stephen Coates)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
GF SECURITIES CO., LTD. 1.07% 17.02 End-of-day quote.4.55%
KANGDE XIN COMPOSITE MATERIAL GROUP CO., LTD. -1.12% 3.52 End-of-day quote.0.00%
KANGMEI PHARMACEUTICAL CO., LTD. -1.27% 2.34 End-of-day quote.-12.69%
All news about KANGMEI PHARMACEUTICAL CO., LTD.
2020MARKET CHATTER : GF Securities to Rejig Banking Operations After Client's Nearly..
MT
2020Prices of China's Traditional Medicinal Materials Rise Tuesday
MT
2020China vows 'zero tolerance' towards illegal market behaviour
RE
2020KANGMEI PHARMACEUTICAL CO., LTD. : annual earnings release
2020China's securities watchdog pledges to clean up financial markets
RE
2019China's Kangmei Pharma sinks by daily limit as watchdog accuses it of fraud
RE
2019Chinese firms' missing $6 billion tests regulators' resolve
RE
2019As China pushes traditional medicine globally, illegal wildlife trade flouris..
RE
More news
Financials
Sales 2019 11 446 M 1 766 M 1 766 M
Net income 2019 -4 661 M -719 M -719 M
Net Debt 2019 31 913 M 4 923 M 4 923 M
P/E ratio 2019 -3,77x
Yield 2019 -
Capitalization 11 788 M 1 818 M 1 819 M
EV / Sales 2018 4,67x
EV / Sales 2019 4,41x
Nbr of Employees 9 209
Free-Float 51,2%
Chart KANGMEI PHARMACEUTICAL CO., LTD.
Duration : Period :
Kangmei Pharmaceutical Co., Ltd. Technical Analysis Chart | 600518 | CNE0000017M1 | MarketScreener
Technical analysis trends KANGMEI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Guo Wei Liu General Manager
Xing Gu Ma Chairman
Jing Ke Chairman-Supervisory Board
Jin Cheng Wan Chief Financial Officer & Director
Zhen Ping Jiang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KANGMEI PHARMACEUTICAL CO., LTD.-12.69%1 801
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035